CG Oncology (NASDAQ:CGON) Stock: Insider Leonard Post Sells 1,000 Shares

Key Points

  • Director Leonard Post sold 1,000 shares at $92 each for $92,000, cutting his direct stake by 50% to 1,000 shares.
  • CG Oncology reported a quarterly loss of $0.64 per share, narrower than analysts’ expected $0.83 loss, while revenue of $1.6 million also exceeded estimates.
  • Analysts’ average rating is “Moderate Buy,” with a $96.11 average price target; HC Wainwright raised its target to $115 and Truist to $100. Preliminary trial results are expected to be followed by fuller data in December.

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the business's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $92.00, for a total value of $92,000.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company's stock, valued at approximately $92,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

CG Oncology Price Performance

Shares of CG Oncology stock opened at $78.94 on Wednesday. The company has a market capitalization of $7.05 billion, a P/E ratio of -28.60 and a beta of 0.35. The business has a 50-day moving average of $68.35 and a two-hundred day moving average of $66.82. CG Oncology, Inc. has a 1 year low of $37.01 and a 1 year high of $93.95.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The business had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.55 million. On average, equities analysts anticipate that CG Oncology, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows




Several institutional investors and hedge funds have recently modified their holdings of CGON. Fiduciary Financial Advisors acquired a new stake in CG Oncology in the 2nd quarter valued at approximately $28,000. Manchester Capital Management LLC lifted its stake in CG Oncology by 2,895.5% in the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company's stock valued at $47,000 after acquiring an additional 637 shares in the last quarter. Covestor Ltd lifted its stake in CG Oncology by 72.6% in the 3rd quarter. Covestor Ltd now owns 770 shares of the company's stock valued at $55,000 after acquiring an additional 324 shares in the last quarter. GAMMA Investing LLC boosted its position in CG Oncology by 47.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,081 shares of the company's stock worth $77,000 after acquiring an additional 350 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new position in CG Oncology during the 1st quarter worth approximately $74,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Top CG Oncology Stories

These are some of the CGON stories that stood out recently:

  • Positive Sentiment: Analysts raised their targets following the news: HC Wainwright increased its target to $115 and reaffirmed Buy, Truist raised its target to $100 and reaffirmed Buy, and Wedbush lifted its target to $91 with an Outperform rating. HC Wainwright ratings
  • Neutral Sentiment: The topline results are preliminary, and the company expects to present fuller trial data in December. Its BLA submissions are planned for 2027, leaving regulatory review and timing as important milestones. Reuters trial coverage
  • Negative Sentiment: Director Leonard E. Post sold 1,000 shares for $92,000, reducing his direct holding by half. The sale may weigh modestly on sentiment, though it is small relative to the company’s overall market value. SEC ownership filing

Wall Street Analyst Weigh In

CGON has been the topic of a number of research reports. Wall Street Zen raised shares of CG Oncology from a "strong sell" rating to a "sell" rating in a research note on Saturday, November 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of CG Oncology in a research report on Thursday, October 15th. Truist Financial reissued a "buy" rating and set a $100.00 price objective (up from $85.00) on shares of CG Oncology in a research report on Tuesday. HC Wainwright raised their price objective on shares of CG Oncology from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Piper Sandler boosted their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $96.11.

Get Our Latest Report on CGON

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Recommended Stories

Insider Buying and Selling by Quarter for CG Oncology (NASDAQ:CGON)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at CG Oncology?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for CG Oncology and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles